Gynecologic Oncology | Specialty

The gynecologic oncology condition center is a comprehensive resource for clinical news and expert insights on gynecologic oncology. Read more at OncLive.

Emerging Agents and Paradigm Shifts in Gynecologic Cancer: Expert Takeaways From ESMO 2025

October 28th 2025

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer

October 23rd 2025

WES-aneuploidy scores may identify patients with dMMR endometrial cancer who do not benefit from the addition of immunotherapy to chemotherapy.

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer

October 20th 2025

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.

Atezolizumab Plus Chemotherapy Demonstrates Noninferior Survival Vs Chemotherapy Alone in Advanced/Recurrent Endometrial Cancer

October 19th 2025

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer

October 16th 2025

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer

October 15th 2025

Chemoradiotherapy improved survival vs radiotherapy alone in the adjuvant setting in high-risk endometrial cancer, particularly in p53-abnormal disease.

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer

October 15th 2025

Maintenance rucaparib showed efficacy in recurrent/metastatic endometrial cancer after the completion of first- or second-line chemotherapy.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews

October 13th 2025

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025

October 10th 2025

See poll results highlighting the top gynecologic oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

October 6th 2025

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress

October 1st 2025

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Northwell Cancer Institute Unveils $14M Center for Women's Cancer, Creating an Integrated Care Model With Comprehensive Services in One Location

September 30th 2025

The Northwell Cancer Institute unveiled its Center for Women's Cancer at the R.J. Zuckerberg Cancer Center.

Recognizing the Rapidly Changing World of Surgical Oncology

September 29th 2025

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

ASCENT-GYN-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer

September 26th 2025

Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.

Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Is Crucial for Endometrial Cancer Risk Reduction

September 23rd 2025

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.

Dr Slomovitz on the Importance of Education on Disease Management and Prevention During Gynecologic Cancer Awareness Month

September 23rd 2025

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Dr Farolfi on a Real-World Study of Bevacizumab Plus SOC Therapy in Cervical Cancer

September 19th 2025

Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.

Advances in Surgical Approaches and Targeted Therapies Highlight Progress in Uterine Cancer

September 18th 2025

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.